+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Miglustat"

Lysosomal Disease Treatment Global Market Report 2024 - Product Thumbnail Image

Lysosomal Disease Treatment Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Gaucher's disease type I - Pipeline Insight, 2024 - Product Thumbnail Image

Gaucher's disease type I - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
From
From
From
Sandhoff Disease Market Report and Forecast 2024-2032 - Product Thumbnail Image

Sandhoff Disease Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 180 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Miglustat is a drug used to treat endocrine and metabolic disorders. It is used to treat Gaucher disease type 1, a rare genetic disorder that affects the body's ability to break down and store fat. It is also used to treat Niemann-Pick disease type C, a rare genetic disorder that affects the body's ability to break down and store cholesterol. Miglustat works by inhibiting the enzyme glucosylceramide synthase, which is responsible for the production of glucosylceramide, a molecule that accumulates in the cells of patients with these diseases. Miglustat is available in both oral and intravenous formulations. It is marketed by several pharmaceutical companies, including Actelion Pharmaceuticals, Sanofi, and Shire. It is also available as a generic drug in some countries. Companies in the Miglustat market include Actelion Pharmaceuticals, Sanofi, Shire, and generic drug manufacturers. Show Less Read more